Oncolytics Biotech Inc. (ONCY)
ONCY trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | ONCY on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Canada |
| IPO year | Not reported by the screener |
| SEC CIK | 0001129928 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | NV |
Financials
No annual revenue filed since the period ending 2021-12-31.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "These conditions raise substantial doubt about our ability to continue as a going concern." | 10-Q 2026-11-13 |
| Cash and burn | $4.1M cash; operating cash flow -$6.1M a quarter. | Report 2026-06-30 |
| Shares outstanding | 136,140,469 (2026-11-13); 74,423,960 three years earlier. | Cover page 2026-11-13 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the market | Latest 2026-04-06 |
| Exchange deficiency notices, 12 months | 1 (8-K item 3.01) | 8-K 2026-07-24 |
| Auditor | Ernst & Young LLP, Calgary, Canada; changed auditors 1 time in 24 months | 8-K 4.01 2026-07-08 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $363K, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | Not filed | -$9.4M | -$8.1M | $4.1M | No debt tags | Needs four quarters | 10-Q 2026-08-12 |
| Q1 2026 2026-03-31 | Not filed | -$9.2M | -$7.3M | $5.5M | No debt tags | Needs four quarters | 10-Q 2026-05-14 |
| Q2 2025 2025-06-30 | Not filed | -$5.3M | -$4.1M | $10.7M | No debt tags | Needs four quarters | 10-Q 2026-08-12 |
| Q1 2025 2025-03-31 | Not filed | -$4.7M | -$4.7M | $10.6M | No debt tags | Needs four quarters | 10-Q 2026-05-14 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-04-06 |
| Latest annual report | 10-K | 2026-03-30 |
| Latest quarterly / interim | 10-Q | 2026-11-13 |
| Latest current report | 8-K | 2026-11-12 |
| Latest proxy | DEFA14A | 2026-10-06 |
Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -15.9% |
| 1 month | -24.5% |
| 3 months | -53.8% |
| Year to date | -57.5% |
| 1 year | -65.7% |
| From 52-week high | -70.9% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| HYFT | MindWalk Holdings Corp. | $0.9378 | -8.95% | $44.6M |
| TLPH | Talphera Inc. | $0.8609 | -4.98% | $44.7M |
| NMAD | Nomad Power Solutions Inc. | $2.80 | +19.15% | $45.1M |
| MIST | Milestone Pharmaceuticals Inc. Common Shares | $0.3650 | -29.81% | $45.4M |
| RNXT | RenovoRx Inc. | $0.9549 | -8.18% | $46.1M |
| PLRX | Pliant Therapeutics Inc. | $0.6932 | -0.55% | $43.0M |
| ANVS | Annovis Bio Inc. | $0.7500 | -19.02% | $46.5M |
| IBO | Impact BioMedical Inc. | $4.91 | -4.47% | $42.4M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier